The US FDA gives Zydus final approval for its bacterial infections pills

1 Sep 2023 , 02:23 PM

Erythromycin Tablets USP, 250 mg And 500 mg, which are used to treat a wide range of bacterial infections, have been given final approval by the United States Food and Drug Administration (USFDA), according to a statement released by Zydus Lifesciences Ltd. on Thursday.

Tablets containing erythromycin are part of a group of antibiotics called macrolides that are also used to treat infections in many different areas of the body, including the respiratory tract, the skin, the intestinal tract, diphtheria, acute pelvic inflammatory disease, legionnaire’s disease, pertussis, and syphilis.

According to the company’s official statement, the medications will be produced at the group’s formulation production facility in Moraiya, Ahmedabad.

With this, the group has now received approval for 350 products, the most recent of which is the 2.5 mg and 20 mg Lenalidomide Capsule, which is used to treat various malignancies. Prior to this, the business received the US FDA’s final approval on March 2 for Acyclovir Cream, 5%, a medication used to treat cold sores on the lips and face.

The US FDA gave its final approval to Zydus Life’s Apixaban tablets, 2.5 mg and 5 mg, and to its Olmesartan Medoxomil & Hydrochlorothiazide tabs, which are intended to treat high blood pressure and prevent major blood clots, respectively.

For feedback and suggestions, write to us at [e-mail]